JPH05504482A - ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体 - Google Patents
ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体Info
- Publication number
- JPH05504482A JPH05504482A JP3504845A JP50484591A JPH05504482A JP H05504482 A JPH05504482 A JP H05504482A JP 3504845 A JP3504845 A JP 3504845A JP 50484591 A JP50484591 A JP 50484591A JP H05504482 A JPH05504482 A JP H05504482A
- Authority
- JP
- Japan
- Prior art keywords
- ige
- cells
- antibody
- peptide
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 147
- 210000004027 cell Anatomy 0.000 claims description 167
- 239000012528 membrane Substances 0.000 claims description 69
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 108060003951 Immunoglobulin Proteins 0.000 claims description 28
- 102000018358 immunoglobulin Human genes 0.000 claims description 28
- 108020004999 messenger RNA Proteins 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 210000003651 basophil Anatomy 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 210000003630 histaminocyte Anatomy 0.000 claims description 13
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 230000001472 cytotoxic effect Effects 0.000 claims description 10
- 229940072221 immunoglobulins Drugs 0.000 claims description 10
- 239000002596 immunotoxin Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 108700012359 toxins Proteins 0.000 claims description 8
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 230000003302 anti-idiotype Effects 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 229940051026 immunotoxin Drugs 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 6
- 230000009870 specific binding Effects 0.000 claims description 6
- 230000002637 immunotoxin Effects 0.000 claims description 5
- 231100000608 immunotoxin Toxicity 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000002101 lytic effect Effects 0.000 claims description 2
- 108010091748 peptide A Proteins 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 108010066676 Abrin Proteins 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 241001669573 Galeorhinus galeus Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 235000015277 pork Nutrition 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 108010029485 Protein Isoforms Proteins 0.000 description 44
- 102000001708 Protein Isoforms Human genes 0.000 description 44
- 238000000034 method Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 239000000047 product Substances 0.000 description 18
- 230000002163 immunogen Effects 0.000 description 17
- 210000000170 cell membrane Anatomy 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 14
- 206010020751 Hypersensitivity Diseases 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 241000283707 Capra Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000013615 primer Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 7
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 101150067056 Epsilon gene Proteins 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical group CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 101150087426 Gnal gene Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100022377 Homeobox protein DLX-2 Human genes 0.000 description 1
- 101000901635 Homo sapiens Homeobox protein DLX-2 Proteins 0.000 description 1
- 101000908580 Homo sapiens Spliceosome RNA helicase DDX39B Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100024690 Spliceosome RNA helicase DDX39B Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000013045 cell staining test Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- -1 properties Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150116497 sacm1l gene Proteins 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.B細胞の膜に結合した免疫グロブリンに特異的に結合するか、分泌型の免疫 グロブリンには特異的に結合しない抗体調製物。 2.前記免疫グロブリンはヒトIgEである請求項1記載の抗体調製物。 3.モノクローナルである請求項1記載の抗体調製物。 4.免疫グロブリンの膜固定ペプチドにより少なくとも部分的に形成されるエピ トープに特異的に結合する抗体調製物。 5.前記免疫グロブリンはヒトIgEである請求項4記載の抗体調製物。 6.前記エピトープは免疫グロブリン鎖の膜結合領域の細胞外部分上に存在する 請求項4記載の抗体調製物。 7.B細胞の表面上のヒトIgEに結合するが、好塩基球の表面上のヒトIgE 及び分泌された可溶性IgEには結合しないモノクローナル抗体。 8.ヒト抗体又は抗体断片である請求項7記載のモノクローナル抗体。 9.B細胞の表面上のIgEに特異的に結合するが、好塩基球の表面上のIgE 及び分泌された可溶性1gEに結合せず、ネズミ科動物の抗原結合領域とヒトH 鎖定常領域とを有するキメラ抗体。 10.B細胞の表面上のヒトIgEに結合するが、好塩基球の表面上のヒトIg E及び分泌された可溶性IgEには結合しないモノクローナル抗体を産生する連 続的で安定なセルライン。 11.ハイブリドーマである請求項10記載のセルライン。 12.IgE担持B細胞には結合するが好塩基球及び分泌された可溶性IgEに は結合しない抗体のL鎖又はH鎖の可変領域をコードする機能的に再構成された 遺伝子を含む単離されたDNA。 13.ヒトL鎖又はH鎖の定常領域をコードするDNAに結合された請求項12 記載のDNAを含むDNA構築物。 14.請求項13記載のDNA構築物でトランスフェクトされ、キメラ抗体を分 泌するミエローマ細胞。 15.IgE担持B細胞に結合するか好塩基球及び分泌された可溶型のIgEに は結合しない抗体のパラトープに対して特異的なモノクローナル抗イディオタイ プ抗体。 16.ネズミ科動物由来の抗原結合領域とヒト由来の定常領域を有するキメラ抗 体である、請求項15記載のパラトープ特異的抗イディオタイプ抗体。 17.請求項16記載の抗イディオタイプ抗体の抗原結合断片。 18.IgE担持B細胞に結合するが、好塩基球及び分泌された可溶性IgEに は結合しない抗体に結合した細胞毒素を含む免疫毒素。 19.前記細線毒素は細胞障害性ステロイド、ゲロニン、アブリン、リシン、シ ュードモナス属毒素、ジフテリア毒素、ポークウィード抗ウィルスペプチド、ト リカセカム、放射性核種及び膜溶解酵素から選ばれる請求項18記載の免疫毒素 。 20.IgE産生Bリンパ球に結合するがマスト細胞、好塩基球及び分泌された 可溶性IgEには結合しない第1の特異的結合剤と、細胞障害性細胞のレセプタ ーに結合する第2の特異的結合剤とを含む二特異的分子。 21.二特異的抗体である請求項20記載の二特異的分子。 22.B細胞の表面上のIgEの膜結合領域の細胞外部分に対応するアミノ酸配 列を有するペプチド。 23.【配列があります】 のアミノ酸配列を有する請求項22記載のペプチド及び該ペプチドの免疫学的性 質を実質的に変化させないその修飾物。 24.請求項23記載のペプチドと反応するモノクローナル抗体又は抗体断片。 25.Cε4エクソン、εm1エクソン及びεm2エクソンのスプライシング以 外のmRNAスプライシングに起因するε免疫グロブリン膜固定ペプチド。 26.請求項25記載のペプチドをコードするヌクレオチド断片。 27.GLAGG・SAQSQ・RAPDR・VLCHS・GQQQG・LPR AA・GGSVP・HPRCH・CGAGR・ADWPG・PPの配列を有する ペプチド部分及び免疫学的性質が実質的に変化しないその修飾物。 28.GAAVP・LSHAA・GEAPD・LPRLH・QRPPA・PRL GR・GHSRS・TRPSF・FSASAの配列を有するペプチド部分及び免 疫学的性質か実質的に変化しないその修飾物。 29.請求項27又は28記載のペプチド部分をコードするヌクレオチド断片。 30.【配列があります】で示される配列又は同一のペプチドをコードする配列 を含むDNA断片。 31.【配列があります】 で示される配列又は同一のペプチドをコードする配列を含むDNA断片。 32.請求項27又は28記載のペプチドに対するモノクローナル抗体。 33.ヒト型又はネズミ科動物/ヒトキメラ型である請求項32記載のモノクロ ーナル抗体及び抗体断片。 35.請求項32記載の抗体に対する抗イディオタイプ抗体。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/468,766 US5260416A (en) | 1987-12-31 | 1990-01-23 | Antigenic epitopes present on membrane-bound but not secreted IgE |
US468,766 | 1990-01-23 | ||
US515,604 | 1990-04-27 | ||
US07/515,604 US5274075A (en) | 1987-12-31 | 1990-04-27 | Newly identified human epsilon immunoglobulin peptides and related products |
US63007790A | 1990-12-19 | 1990-12-19 | |
US630,077 | 1990-12-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05504482A true JPH05504482A (ja) | 1993-07-15 |
JP3449712B2 JP3449712B2 (ja) | 2003-09-22 |
Family
ID=27413084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50484591A Expired - Lifetime JP3449712B2 (ja) | 1990-01-23 | 1991-01-23 | ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0512064B1 (ja) |
JP (1) | JP3449712B2 (ja) |
AT (1) | ATE154637T1 (ja) |
AU (2) | AU645783B2 (ja) |
CA (1) | CA2074089C (ja) |
DE (1) | DE69126607T2 (ja) |
DK (1) | DK0512064T3 (ja) |
ES (1) | ES2107454T3 (ja) |
GR (1) | GR3024563T3 (ja) |
HK (1) | HK1002034A1 (ja) |
SG (1) | SG70982A1 (ja) |
WO (1) | WO1991011456A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009509538A (ja) * | 2005-09-29 | 2009-03-12 | メディミューン,エルエルシー | 膜Ig特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
JP2010521989A (ja) * | 2007-03-22 | 2010-07-01 | ジェネンテック, インコーポレイテッド | アポトーシス性抗IgE抗体 |
JP2014512361A (ja) * | 2011-04-06 | 2014-05-22 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 病原性疾患における細菌mamポリペプチドの調節 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2196009T3 (es) * | 1992-07-08 | 2003-12-16 | Unilever Nv | Procedimiento para inmovilizar enzimas en la pared celular de una celula microbiana mediante la produccion de una proteina de fusion. |
DE69332521T2 (de) * | 1993-03-11 | 2003-10-02 | Tanox Biosystems Inc | ANTIGENE EPITOPE VON IgE REPRÄSENTIERENDEN PEPTIDEN AUF DER B-ZELL-OBERFLÄCHE ABER NICHT AUF OBERFLÄCHEN VON BASOPHILEN |
US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
HUP9901109A3 (en) | 1996-03-01 | 1999-11-29 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2486464A1 (en) * | 2002-05-21 | 2003-11-27 | Resistentia Pharmaceuticals Ab | Chimeric ige polypeptides and host cells |
CN105012953B (zh) | 2005-07-25 | 2018-06-22 | 阿普泰沃研发有限责任公司 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
US20090220416A1 (en) * | 2006-05-03 | 2009-09-03 | Sydney Welt | Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders |
RU2487888C2 (ru) | 2006-06-12 | 2013-07-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Одноцепочечные мультивалентные связывающие белки с эффекторной функцией |
AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
ATE513856T1 (de) | 2008-04-11 | 2011-07-15 | Emergent Product Dev Seattle | Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon |
HUE036920T2 (hu) | 2009-02-25 | 2018-08-28 | Academia Sinica | Anti-C[epszilon]mX-ellenanyagok, amelyek képesek B-limfocitákon humán mlgE-hez kötõdni |
WO2013158274A1 (en) | 2012-04-20 | 2013-10-24 | Academia Sinica | ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS |
US10196458B2 (en) * | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
TWI603979B (zh) * | 2013-12-05 | 2017-11-01 | 中央研究院 | 抗人類膜錨定型免疫球蛋白a抗體能夠溶解帶有膜錨定型免疫球蛋白a的b淋巴球與降低免疫球蛋白a 的生產 |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
WO2019085902A1 (en) | 2017-10-31 | 2019-05-09 | Fountain Biopharma Inc. | Treating ige-mediated allergic diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT89107A (pt) * | 1987-11-30 | 1989-11-30 | Idec Pharma Corp | Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas |
DE3853636T3 (de) * | 1987-12-31 | 1999-04-08 | Tanox Biosystems Inc | Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden. |
-
1991
- 1991-01-23 EP EP91904413A patent/EP0512064B1/en not_active Expired - Lifetime
- 1991-01-23 JP JP50484591A patent/JP3449712B2/ja not_active Expired - Lifetime
- 1991-01-23 AT AT91904413T patent/ATE154637T1/de not_active IP Right Cessation
- 1991-01-23 DK DK91904413.1T patent/DK0512064T3/da active
- 1991-01-23 SG SG1996006487A patent/SG70982A1/en unknown
- 1991-01-23 DE DE69126607T patent/DE69126607T2/de not_active Expired - Lifetime
- 1991-01-23 WO PCT/US1991/000491 patent/WO1991011456A1/en active IP Right Grant
- 1991-01-23 AU AU73179/91A patent/AU645783B2/en not_active Expired
- 1991-01-23 CA CA002074089A patent/CA2074089C/en not_active Expired - Lifetime
- 1991-01-23 ES ES91904413T patent/ES2107454T3/es not_active Expired - Lifetime
-
1993
- 1993-12-03 AU AU52148/93A patent/AU5214893A/en not_active Abandoned
-
1997
- 1997-08-28 GR GR970402202T patent/GR3024563T3/el unknown
-
1998
- 1998-02-12 HK HK98101073A patent/HK1002034A1/xx not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009509538A (ja) * | 2005-09-29 | 2009-03-12 | メディミューン,エルエルシー | 膜Ig特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
JP2013126984A (ja) * | 2005-09-29 | 2013-06-27 | Medimmune Llc | 膜Ig特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
JP2010521989A (ja) * | 2007-03-22 | 2010-07-01 | ジェネンテック, インコーポレイテッド | アポトーシス性抗IgE抗体 |
JP2014512361A (ja) * | 2011-04-06 | 2014-05-22 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 病原性疾患における細菌mamポリペプチドの調節 |
US9529005B2 (en) | 2011-04-06 | 2016-12-27 | The Board Of Regents Of The University Of Texas System | Modulating bacterial MAM polypeptides in pathogenic disease |
Also Published As
Publication number | Publication date |
---|---|
AU645783B2 (en) | 1994-01-27 |
ATE154637T1 (de) | 1997-07-15 |
GR3024563T3 (en) | 1997-12-31 |
EP0512064B1 (en) | 1997-06-18 |
CA2074089A1 (en) | 1991-07-24 |
JP3449712B2 (ja) | 2003-09-22 |
DE69126607T2 (de) | 1998-01-15 |
EP0512064A1 (en) | 1992-11-11 |
SG70982A1 (en) | 2000-03-21 |
HK1002034A1 (en) | 1998-07-24 |
CA2074089C (en) | 2001-04-10 |
AU7317991A (en) | 1991-08-21 |
ES2107454T3 (es) | 1997-12-01 |
DK0512064T3 (da) | 1997-12-15 |
DE69126607D1 (de) | 1997-07-24 |
WO1991011456A1 (en) | 1991-08-08 |
EP0512064A4 (en) | 1993-02-17 |
AU5214893A (en) | 1994-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5342924A (en) | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor | |
JPH05504482A (ja) | ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体 | |
US5254671A (en) | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor | |
CA1340233C (en) | Antigenic epitopes of immunoglobulin e present on b cell but not basophil surface | |
US5231026A (en) | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE | |
RU2047177C1 (ru) | Способ определения b-лимфоцитов, продуцирующих ige | |
US5292867A (en) | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin | |
KR101637502B1 (ko) | 치료용 개 면역글로불린 및 이를 이용하는 방법 | |
KR101833465B1 (ko) | 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 | |
WO2021227940A1 (zh) | 抗tigit的抗体、其制备方法和应用 | |
WO1992007574A1 (en) | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells | |
JPH04504424A (ja) | 膜結合IgAに存在するが分泌IgAに存在しない抗原エピトープ | |
WO1997043316A1 (en) | Physiologically active molecules with extended half-lives and methods of using same | |
US5281699A (en) | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins | |
KR100559918B1 (ko) | 강화 백신 | |
FR3075200A1 (fr) | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc | |
US5298420A (en) | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface | |
CN113631582A (zh) | 一种融合蛋白及其用途 | |
US5252467A (en) | Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE | |
US5260416A (en) | Antigenic epitopes present on membrane-bound but not secreted IgE | |
US5274075A (en) | Newly identified human epsilon immunoglobulin peptides and related products | |
JP2852705B2 (ja) | 自己免疫疾患の治療 | |
WO2022063194A1 (zh) | 靶向cpsg4的人源化嵌合抗原受体及表达该嵌抗原受体的免疫效应细胞及其应用 | |
EP0644896A1 (en) | PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE | |
WO2000023477A2 (en) | Immunoglobulin variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080711 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090711 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090711 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100711 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110711 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110711 Year of fee payment: 8 |